Table 3.
Multivariate analysis for progression free survival.
| Variant | Hazard ratio | 95% CI (Lower) | 95% CI (Upper) | p-value |
|---|---|---|---|---|
| Age at diagnosis, n | ||||
| <40 y | 1 | |||
| 40–64 y | 1.701 | 0.778 | 3.720 | 0.184 |
| >64 y | 2.139 | 0.907 | 5.046 | 0.082 |
| Extent of surgical resection, n | ||||
| Gross total resection | 1 | |||
| Subtotal resection | 3.142 | 1.944 | 5.077 | 0.000 |
| Biopsy | 1.174 | 0.754 | 1.828 | 0.477 |
| Comorbidities at diagnosis, n | ||||
| Hypertension | 0.882 | 0.616 | 1.263 | 0.494 |
| Ischemic heart disease | 1.484 | 2.007 | 9.702 | 0.000 |
| RT total dose (Gy), n | ||||
| ≥56 | 1 | |||
| 36–50 | 0.787 | 0.365 | 1.694 | 0.540 |
| ≤32 | 8.138 | 2.760 | 23.992 | 0.000 |
| No. of adjuvant Temozolomide cycles*, n | ||||
| 0 | 1 | |||
| 1–3 | 0.734 | 0.304 | 1.774 | 0.493 |
| 4–6 | 0.631 | 0.258 | 1.540 | 0.312 |
| 7–9 | 0.229 | 0.085 | 0.612 | 0.003 |
| ≥10 | 0.156 | 0.064 | 0.377 | 0.000 |
| Waiting time until concomitant therapy with RT + TMZ, d | ||||
| <28 days | 1 | |||
| 28–42 days | 0.834 | 0.530 | 1.313 | 0.433 |
| ≥42 days | 0.514 | 0.330 | 0.799 | 0.003 |
| *Post concomitant therapy with RT + TMZ. | ||||
Hazard ratio (HR) less than 1 – better overall survival, > 1 – worse overall survival; P-value < 0.05 – statistically significant.